Navigation Links
Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Date:4/6/2009

COSTA MESA, Calif., April 6 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced today that company Chairman and CEO, Chris Stern, has posted a new entry on his blog on the company website. The latest blog discusses the company's recent meetings in Zurich, Switzerland, further development plans for Oxycyte(R) in indications beyond traumatic brain injury, supply plans for clinical-grade Oxycyte, and plans for raising additional capital.

The blog is available on the company's Electronic Shareholder Forum which can be found via the Investor Relations page of the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
2. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
3. Oxygen Biotherapeutics, Inc. Expands Board of Directors
4. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
5. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
6. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
7. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
8. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
9. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
10. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to a new market report published by ... was valued at USD 3,754.6 million in 2012 and is ... a CAGR of 5.9% from 2013 to 2019. , Nearly ... afflicted by bone and joint disorders, and this number is ... and will continue to increase the demand for orthobiologics. Other ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... 29, 2014 Three Lawrence Livermore ... Hydrogen Production R&D Award for their ... water using sunlight. , Shared with collaborators from ... University of Nevada, Las Vegas (UNLV), the award ... of photoelectrochemical solar-hydrogen production and corrosion processes. , ...
(Date:8/29/2014)... MA (PRWEB) August 29, 2014 A ... in the biotech start-up dense realm of Boston-Cambridge, is ... and able investors. James Sherley, the Director of Boston’s ... increasing the local and national visibility of his company ... September 2013. , In addition to a social media ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... Exagen Diagnostics, Inc. , a specialty focused ... tests for rheumatologists and gastroenterologists, announced today the appointment ... Tornoe has more than 20 years of ... making him a key hire as Exagen broadens its ...
... LOS ANGELES, Aug. 10, 2011 Genesis Biopharma, ... cancer immunotherapies, today announced it has signed a ... National Cancer Institute (NCI).  Under the terms of ... Biopharma will work with Steven A. Rosenberg, M.D., ...
... DIEGO, Aug. 9, 2011 Verenium Corporation (Nasdaq: ... development and commercialization of high-performance enzymes, today reported a summary ... quarter and six months ended June 30, 2011. ... terms of product revenues and partnership negotiations in the first ...
Cached Biology Technology:Eric Tornoe Joins Exagen Diagnostics as President and COO 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9
(Date:8/28/2014)... Yale University researchers have identified a handful of bacterial ... as Crohn,s disease and ulcerative colitis, using patients, own ... are published Aug. 28 in the journal Cell ... intestinal microbiota, which plays a critical role in the ... only a small number of bacterial species affect a ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program has ... of Human Genetics from October 18 22, 2014 ... to promote the entry of students, post doctorates and ... basic science community and to encourage the participation of ... This year MARC conferred 16 awards totaling $29,600., ...
(Date:8/28/2014)... The support of peer groups and clinicians ... programs, according to recent University of Georgia research. ... the Athens-Clarke County area determined that role models ... of mothers of infants. , "Mothers who received ... at breastfeeding," said study co-author Alex Anderson, an ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2Breastfeeding study shows need for effective peer counseling programs 2
... is available in German . , ... species of the Galapagos archipelago, treks slowly and untiringly ... Institute for Ornithology in Radolfzell, together with the Charles ... acceleration measurements to find out that especially the dominant ...
... A study published in the current issue ... available on-line at http://www.ingentaconnect.com/content/cog/ct/ , has found ... (SM-MSCs) or adipose tissue (ADSCs) were injected into ... laboratory rats that had suffered a myocardial infarction, ...
... more than 200 million people every year mainly in ... the Plasmodium parasite, which is spread by infected ... but more than half a million people nevertheless die every ... during the past decade have reduced the distribution of the ...
Cached Biology News:Galapagos tortoises are a migrating species 2Galapagos tortoises are a migrating species 3Study suggests different organ-derived stem cell injections improve heart function 2New method for diagnosing malaria 2
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
... Life Science FLA-8000 Fluorescent Image Analyzer features ... single laser imaging system. This powerful new ... with fluorescent dyes or radioisotopes at resolutions ... laboratories. Speed, image quality and flexibility make ...
...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Biology Products: